Longbio Pharma Presented Positive Topline Phase 1 Results for LP-003 at ERS2023
Phase II is coming! LP-003 is expected to become the first biomedicine to treat allergic rhinitis in China!
The IND application of LP-005, the first complement pipeline of Longbio has accepted by the CDE
Longbio to present during the 41th JPM Healthcare Conference
Longbio will attend the 6th BFC Conference on Jan. 8 at St. Regis San Francisco during JPM Healthcare Conference 2023.
Longbio Pharma is a biotech company located in Shanghai, China. The company, which was founded in 2018, is focused on allergy and complement diseases, serving patients and society. LongBio aims to bring our drugs to both domestic and international markets with our partners, especially to bring patients with more affordable and high-quality bio-medicines.
Focus on development of the innovational drugs
in allergy and complement diseases